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Original ArticleInfusion of donor feces affects the gutebrain
axis in humans with metabolic syndromeAnnick V. Hartstra 1, Valentina Schüppel 2, Sultan Imangaliyev 1, Anouk Schrantee 3, Andrei Prodan 1,
Didier Collard 1, Evgeni Levin 1, Geesje Dallinga-Thie 1, Mariette T. Ackermans 4, Maaike Winkelmeijer 1,
Stefan R. Havik 1, Amira Metwaly 2, Ilias Lagkouvardos 5, Anika Nier 6, Ina Bergheim 6,
Mathias Heikenwalder 7, Andreas Dunkel 8, Aart J. Nederveen 3, Gerhard Liebisch 9, Giulia Mancano 10,
Sandrine P. Claus 10, Alfonso Benítez-Páez 11, Susanne E. la Fleur 4, Jacques J. Bergman 12, Victor Gerdes 1,
Yolanda Sanz 11, Jan Booij 3, Elles Kemper 13, Albert K. Groen 1, Mireille J. Serlie 14, Dirk Haller 2,5,
Max Nieuwdorp 1,*ABSTRACT
Objective: Increasing evidence indicates that intestinal microbiota play a role in diverse metabolic processes via intestinal butyrate production.
Human bariatric surgery data suggest that the gut-brain axis is also involved in this process, but the underlying mechanisms remain unknown.
Methods: We compared the effect of fecal microbiota transfer (FMT) from post-Roux-en-Y gastric bypass (RYGB) donors vs oral butyrate
supplementation on (123I-FP-CIT-determined) brain dopamine transporter (DAT) and serotonin transporter (SERT) binding as well as stable
isotope-determined insulin sensitivity at baseline and after 4 weeks in 24 male and female treatment-naïve metabolic syndrome subjects. Plasma
metabolites and fecal microbiota were also determined at these time points.
Results: We observed an increase in brain DAT after donor FMT compared to oral butyrate that reduced this binding. However, no effect on body
weight and insulin sensitivity was demonstrated after post-RYGB donor feces transfer in humans with metabolic syndrome. Increases in fecal
levels of Bacteroides uniformis were significantly associated with an increase in DAT, whereas increases in Prevotella spp. showed an inverse
association. Changes in the plasma metabolites glycine, betaine, methionine, and lysine (associated with the S-adenosylmethionine cycle) were
also associated with altered striatal DAT expression.
Conclusions: Although more and larger studies are needed, our data suggest a potential gut microbiota-driven modulation of brain dopamine
and serotonin transporters in human subjects with obese metabolic syndrome. These data also suggest the presence of a gut-brain axis in
humans that can be modulated.
NTR registration: 4488.
 2020 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords Obesity; Gutmicrobiota; Gut-brain axis; Metabolites1. INTRODUCTION
The worldwide increasing prevalence of obesity and associated
metabolic disorders such as type 2 diabetes mellitus (T2DM) and
cardiovascular disease are of growing concern [1]. Weight loss
strategies based on lifestyle interventions have little long-term
success [2]. Because regulation of feeding behavior and energy
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www.molecularmetabolism.comobesity and metabolic disturbances has been a topic of research for
the past two decades. Many studies have shown a functional gut-
brain axis in which gut-derived peptides, microbiota, metabolites,
and neuronal feedback inform the brain about energy status [3].
These signals then elicit an appropriate feeding and metabolic
response. Dopamine and serotonin are major neurotransmitters
involved in these regulations. Serotonin is involved in the homeo-
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Original Articledopamine regulates the non-homeostatic or rewarding aspects of
food [5]. Recent studies linked a reduction in the cerebral serotonin
transporters (SERT), dopamine transporters (DAT) and dopamine D2/
3 receptor binding to BMI in humans [6e14]. The brain serotonergic
and dopaminergic systems have also been linked to glucose
regulation [15,16].
Some of these effects may be mediated by the gut-brain axis [17] driven
via production of metabolites by intestinal microbiota derived from the
diet [18,19]. The most compelling evidence of the role of the gut-brain
axis in human metabolism comes from post-Roux-en-Y gastric bypass
bariatric surgery (RYGB) studies. RYGB can alter the composition of the
gut microbiota in both mice [20] and humans [21e23], and post-RYGB
fecal microbiota transfer (FMT) in germ-free mice induced weight loss
and improved glucose metabolism [20]. The difference in gut microbiota
composition between obese and lean mice and humans is accompanied
by variations in plasma metabolite profile [24,25], including serotonin
[26,27]. Likewise, weight loss induced by RYGB significantly increased
central SERT in both animals and humans [28e30] and striatal dopa-
mine D2/3 receptor availability in humans [31]. It has recently become
apparent that intestinal bacteria can regulate host serotonin metabolism
[32e34], especially via the kynurenine pathway [35e37]. This pathway
is also involved in the intestinal production of serotonin and dopamine
and has been linked to central regulation of food intake in mice as well
as intestinal passage time [38]. Another route of the gut-brain axis to
modulate central control of food intake and metabolism may be via
production of the short-chain fatty acid (SCFA) butyrate, which in
humans is produced by intestinal bacteria from dietary fiber [39] and
absorbed in the colon where it provides energy for colonic epithelial
cells. It has also been shown to regulate hepatic lipogenesis and
gluconeogenesis in mice on high-fat diets [40,41] and intestinal sero-
tonin production [42,43], increasing SERT in the hypothalamus [44].
Oral butyrate supplementation affected sympathetic tone and intestinal
transit times as well as physical activity and reduced liver fat in mice
[45,46]. Another potential method through which the gut microbiota
may influence the brain includes the bile acids. Gut microbiota syn-
thesize secondary bile acids from primary bile acids via deconjugation
and dihydroxylation, and bile acids are involved in intestinal fat ab-
sorption and regulation of glucose and energy homeostasis [47]. They
function as signaling molecules through their binding potential to the
nuclear receptor farnesoid X receptor (FXR) [48]. Although FXR is pre-
dominantly expressed in the liver and ileum, it can also be found in the
brain, and in mice bile, acid signaling has been associated with
neurological decline via upregulation of FXR [49]. Studies with FMT, a
technique applied in humans for an increasing number of diseases [50],
have contributed to delineate causality from association with respect to
intestinal microbiota and metabolism. Animal studies showed that
infusion of donor feces derived from post-RYGB mice induced weight
loss and improved glucose metabolism with specific increases in
bacteria involved in butyrate production [20]. Accordingly, we previously
showed that infusion of feces from lean male donors in obese insulin-
resistant metabolic syndrome subjects resulted in a temporary increase
in insulin sensitivity and altered intestinal microbial diversity, although
weight loss was not observed [51,52], whereas using feces from obese
donors induced an adverse effect on recipient insulin sensitivity [53].
Regarding the former, a distinct increase in bacteria involved in butyrate
production was observed, similar to results in large metagenome-wide
association human studies in which a decrease in butyrate-producing
bacteria was associated with T2DM [54,55]. However, we recently
showed that in contrast to animal studies [56], orally administered
butyrate had no effect on both insulin sensitivity and energy expenditure
in human metabolic syndrome subjects [53,57]. Causality for a role of2 MOLECULAR METABOLISM 42 (2020) 101076  2020 The Author(s). Published by Elsevier Ggut microbiota composition in human metabolism, probably involving
the gut-brain axis, has yet to be demonstrated.
We therefore studied in a double-blind randomized controlled pilot trial
whether orally administered capsules of butyrate compared to a single
infusion of donor feces derived from post-RYGB patients affects brain
SERT and DAT binding, whole body serotonin metabolism, and small
intestinal tryptophan hydroxylase 1 (TPH1) gene expression as well as
insulin sensitivity in subjects with metabolic syndrome. As secondary
endpoints, we correlated these outcomes with changes in gut micro-
biota composition and plasma metabolites. We also studied changes in
MRI intrahepatic triglycerides (IHTG), sympathetic activity, and intes-




Treatment-naïve omnivorous Caucasian male or post-menopausal
female subjects (n ¼ 24) aged 50e70 years with metabolic syn-
drome were recruited via local advertisements. Subjects were included
if they fulfilled the National Cholesterol Education Program (NCEP)
criteria for metabolic syndrome (3/5: fasting plasma glucose
(FPG)  5.6 mmol/l and/or homeostatic model assessment of insulin
resistance (HOMA-IR)  2.5, triglycerides  1.7 mmol/l, waist
circumference > 102 cm (males)/> 88 cm (females), HDL-
cholesterol  1.04 mmol/l (m)/ 1.30 mmol/l (f) and blood
pressure  130/85 mmHg). HOMA-IR was calculated from fasting
plasma insulin (FPI) and glucose: FPG * (FPI * 6.945)/22.5. Subjects
were excluded if they had used any medication in the prior 3 months.
Other exclusion criteria were pre- or probiotic supplementation, sub-
stance abuse (nicotine, drugs, or alcohol > 2 units/day),
eGFR < 60 ml/min, contraindication for MRI, unstable weight, or
history of a cardiovascular event or psychiatric disorder. As fecal do-
nors, 6 otherwise healthy Caucasian males and post-menopausal fe-
males aged 50e70 years who lost >30% of their body weight 1 year
after RYGB and did not use any medication (barring vitamins) were
selected and recruited by their treating physician at the Bariatric
Surgery Clinic at the former Slotervaart Hospital in Amsterdam. They
completed questionnaires regarding their dietary and bowel habits,
travel history, comorbidity including family history of diabetes mellitus,
and medication use. They were screened for the presence of infectious
diseases as previously published [58]. Male donors donated to males
and female donors to females, and donors could donate to multiple
recipients. This study was conducted at the Amsterdam University
Medical Centers (UMC), Academic Medical Center, in accordance with
the Declaration of Helsinki (updated version 2013) and CONSORT
guidelines. All of the participants provided written informed consent
and all of the study procedures were approved by the institutional
review board (IRB) (ethics committee) of the Amsterdam UMC (Aca-
demic Medical Center). This study was prospectively registered at the
Dutch Trial registry (https://www.trialregister.nl/trial/4488). Patients
were not invited to comment on the study design and were not con-
sulted to develop relevant patient outcomes or interpret the results.
Patients were not invited to contribute to the writing or editing of this
document for readability or accuracy. Data quality and patient safety
were monitored by the Clinical Research Unit staff at the AMC.
2.1.2. Study design
In this double-blind randomized controlled intervention trial, metabolic
syndrome subjects were randomized (using computerizedmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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randomization) to receive either a single autologous fecal trans-
plantation, serving as placebo, followed by 4 g of oral sodium butyrate
tablets (Sensilab, Poland) once daily for 4 weeks, which was the
maximum daily dose allowed by the IRB based on a previous human
intervention study [59] (butyrate group, n ¼ 12) or a single post-RYGB
donor fecal transplantation followed by similar daily amounts of pla-
cebo tablets (similar tablet composition except for butyrate content
produced by Sensilab, Poland) for 4 weeks (post-RYGB FMT group,
n ¼ 12) (Supplementary Figure 1). Compliance was evaluated by
counting the number of capsules returned after 4 weeks of treatment.
At baseline and after 4 weeks, all of the measurements were con-
ducted, including a hyperinsulinemic euglycemic clamp (HIEC), brain
magnetic resonance imaging (MRI), single-photon emission computed
tomography (SPECT) imaging, 1H-liver magnetic resonance spectros-
copy (MRS), sympathetic activity using a plethysmography-based
blood pressure measurement device and small intestinal biopsies
(for TPH1 expression). Fasting plasma, 24 h urine (for 5-
hydroxyindoleacetic acid [5-HIAA] levels), and morning feces were
also collected at these time points. All the participants completed an
online nutritional diary (https://mijn.voedingscentrum.nl/nl/eetmeter) to
monitor their caloric intake of carbohydrates, fat, protein, and fibers.
Physical activity energy expenditure (PAEE) was measured via an
accelerometer (ActiHeart; CamNTech Ltd., Cambridge, UK), and in-
testinal transit time was assessed using Sitzmark capsules as previ-
ously described [53]. For a detailed description of the study design, see
the online supplementary methods.
2.2. Measurements
2.2.1. Fecal transplant procedure
FMT was performed as previously described [53]. Each subject
received a single FMT at baseline, either autologous or allogenic as
determined via a double-blinded randomization procedure. On the
treatment day, the donor delivered fresh morning stools to the hospital.
Each study subject received a duodenal tube via gastroscopy and
underwent colon lavage with 3e4 l of Klean-Prep (macrogol) by a
duodenal tube. Donor feces were diluted in 500 mL of 0.9% saline
solution and filtered through cotton gauze. This produced a 500 ml
filtrate used for the FMT, which each subject received 2 h after bowel
lavage through the duodenal tube via a 50 cc syringe.
2.2.2. Two-step HIEC and resting energy expenditure (REE)
REE was measured in all of the subjects during the final 20 min in both
the basal state and HIEC by indirect calorimetry. Oxygen consumption
and carbon dioxide production were continuously measured for 20 min
using a ventilated hood system (Vmax Encore 29; SensorMedics,
Anaheim, CA, USA). REE was then calculated from each subject’s
oxygen consumption and carbon dioxide production [60]. A 2-step
HIEC clamp was used to measure insulin sensitivity [61]. After an
overnight fast, the subjects visited the clinical trial unit, where they
received 2 catheters in the peripheral veins of both arms. One catheter
was used to infuse [6,6-2H2]glucose and [1,1,2,3,3-
2H5]glycerol
tracers (99% enriched; Cambridge Isotopes, Andover, MA, USA),
glucose 20% enriched with [6,6-2H2]glucose to approximate plasma
enrichment, and insulin (Actrapid; Novo Nordisk Farma, Alphen aan de
Rijn, the Netherlands). The other catheter was used to sample each
subject’s blood, which was arterialized by heating the arm with a
heated hand box at 57 C. Two hours before starting the clamp
(t ¼ 2 h), a primed continuous infusion of both [6,6-2H2]glucose and
[1,1,2,3,3-2H5]glycerol was started and continued until the end of the
experiment. After 2 h (t ¼ 0), 3 samples for glucose, glucose andMOLECULAR METABOLISM 42 (2020) 101076  2020 The Author(s). Published by Elsevier GmbH. This is
www.molecularmetabolism.comglycerol enrichment, free fatty acids (FFAs), and glucoregulatory hor-
mones were sampled, and the first clamp step was started by infusing
insulin at a rate of 20 mU$m2 (body surface area)$min1. Plasma
glucose was measured every 10 min using a glucose analyzer (YSI
2300 Stat Plus Glucose Lactate Analyzer, YSI Life Sciences, Yellow
Springs, Ohio, USA). To maintain plasma glucose at 5 mmol l1, 20%
glucose enriched with [6,6-2H2]glucose was infused at a variable rate.
Insulin infusion was increased after 2 h of insulin infusion (t ¼ 2 h) to
60 mU$m2$min1 for the second clamp step. At t ¼ 2 and 4 h, 5
blood samples were obtained to assess glucose and glycerol enrich-
ment, free fatty acids (FFAs), and glucoregulatory hormones. [6,6-2H2]
glucose and [1,1,2,3,3-2H5]glycerol enrichment was measured as
previously described [62,63]. The rates of appearance (Ra) of glucose
and glycerol and rates of disposal (Rd) of glucose were subsequently
calculated using the modified forms of the Steele equations for (non-)
steady state measurements as previously described [53,61,64]. He-
patic insulin sensitivity was calculated as the percentage suppression
of basal endogenous glucose production (EGP) by insulin during the
first step of the clamp.
2.2.3. Systemic hemodynamics
Blood pressure and central hemodynamics were assessed via a
Nexfin device (Edwards Lifesciences, Irvine, CA, USA) that utilizes the
volume-clamp method to measure blood pressure and heart rate,
while cardiac output was estimated using the CO-trek algorithm [65].
Heart rate variability, a marker of sympathovagal balance, was
determined by calculating the standard deviation of the normal-to-
normal intervals (SDNN, inter-beat intervals derived from contin-
uous blood pressure recordings after filtering) [66]. Non-invasive
continuous finger arterial blood recordings were obtained in the su-
pine position for 10 min after 10 min of rest. All the analyses were
conducted in a blinded fashion.
2.2.4. MRI for anatomical mapping of the brain and 1H MRS for
determining IHTG content
A T1-weighted MRI scan of the brain was performed on each individual
(for anatomical reference to determine diencephalic SERT and striatal
DAT) on a 3.0 T Philips Ingenia scanner (Philips Healthcare, Best, the
Netherlands) with a 16-channel head coil.
IHTG was measured via 1H-MRS conducted on the same scanner using
a 26-channel torso coil. First, T1-weighted coronal and axial localizer
images of the abdomen were obtained that were then used to position
a 20 20 20 mm voxel. Because the diaphragm, edges of the liver,
or other vascular and biliary structures must be avoided, the voxel was
placed in the right hepatic lobe. The acquisition time and voxel size
were standardized for all the subjects. Spectra were obtained using
first-order iterative shimming, a point-resolved spectroscopy (PRESS)
sequence with repetition time/echo time (TR/TE) ¼ 2000/35 ms, and
64 signal averages during free breathing. The liver 1H-MR spectra
were evaluated using jMRUI software. Water non-suppressed spectra
were used to quantify the lipid signal resonances. The relative fat
content was expressed as a ratio of the fat peak area over the cu-
mulative water and fat peak areas (1.3 ppm/([1.3 ppm þ4.65 ppm]).
Calculated peak areas of water and fat were corrected for T2 relaxa-
tion. The IHTG percentage was determined as previously described
[67]. All of the analyses were conducted in a blinded fashion.
2.2.5. Brain SPECT imaging
Each subject underwent SPECT imaging of the brain 2 and 3 h after
intravenous administration of well-validated radioligand 123I-FP-CIT at
a total dose of 115 MBq (range 110e120 MBq; specifican open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 3
Original Articleactivity > 750 MBq/nmol; radiochemical purity > 98%, produced
according to the GMP criteria at GE Healthcare, Eindhoven, the
Netherlands) [68]. This tracer bound to DAT in the striatum and extra-
striatal SERT, which was optimally visualized and quantified in the
SERT-rich (hypo)thalamic region of the brain 2 h after injection and in
the DAT-rich striatum 3 h after injection [69,70]. Figure 1A shows an
example. The subjects were scanned after an overnight fast and
pretreated with potassium iodide for thyroid blockade of free radio-
active iodide. For scanning, the Inspira HD system was used, a brain-
dedicated tomographic SPECT scanner (Neurologica, Boston, MA,
USA), and an acquisition protocol as previously described (slice
thickness 4 mm and acquisition time 180 s/slice) [71]. All the scans
were reconstructed in 3D mode and corrected for attenuation. One
SPECT scan could not be performed in 1 subject in the butyrate group
after treatment due to technical problems with the scanner. On the
SPECT scan day, the subjects scored their hunger and appetite on a
visual analog scale (VAS) as previously described [72].Figure 1: A. Brain SPECT image and ROIs. The top panel shows a representative examp
administration of the radioligand 123I-FP-CIT. In the bottom panel, the regions of interest (R
determine SERT binding in the thalamus and hypothalamus and DAT binding in the stria
hypothalamus. Changes in DAT and SERT binding between group comparisons showed tha
group, resulting in a significant change over time between both groups, while for SERT b
4 MOLECULAR METABOLISM 42 (2020) 101076  2020 The Author(s). Published by Elsevier G2.2.6. ROI analysis
To determine SERT binding in the thalamus and hypothalamus and
DAT binding in the striatum, a region of interest (ROI) analysis was
conducted as previously described [71] (Figure 1A). Striatal and
thalamic masks were obtained from individual T1-weighted MRI scans
using FreeSurfer (version 5.3.0.) [73, 74]. Hypothalamic masks were
then manually drawn on the MRI scans, a reliable method [75], via ITK-
SNAP (version 3.4.0, PICSL, University of Pennsylvania, PA, USA) using
anatomical landmarks as previously described [76]. Activity in the
cerebellum was assumed to represent non-displaceable binding (non-
specific binding and free radioactivity). Individual cerebellar masks
were obtained in the T1-weighted space by warping the cerebellum
(without vermis) as described in the HarvardeOxford subcortical atlas
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases) to the individual T1w MRI
using FSL (FMRIB Software Library, version 5.0.6, Oxford, UK). All the
analyses were conducted in a blinded manner. All the ROIs were then
registered and resliced to the SPECT scan using statistical parametricle of a brain MRI overlaid with a brain SPECT image obtained 2 h after the intravenous
OIs) for specific parts of the human brain are shown, which were subsequently used to
tum. B, C, and D. Changes in striatal DAT as well as SERT binding in thalamus and
t striatal DAT-binding ratios decreased in the butyrate group and increased in the FMT
inding, a trend was observed. *p < 0.05.
mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mapping. A specific to non-specific binding ratio (SNS-BR) was
calculated as (mean ROI-binding - mean non-specific cerebellar
binding)/mean non-specific cerebellar binding), which was used as the
outcome measure (binding potential, BPND).
2.2.7. Laboratory analysis
Plasma biochemistry measurements were performed as described
earlier [57]. Plasma bile acid concentrations were determined using an
LC-MS/MS system as previously described [77]. Fecal short-chain fatty
acids (SCFAs) (butyrate, propionate, and acetate) were determined in
fresh morning fecal samples by HPLC as previously described [78].
Twenty-four hours urine was collected at baseline and after 4 weeks to
assess the concentration of the main metabolite of serotonin 5-HIAA as
a measurement of the whole body serotonin levels as previously re-
ported [79].
2.2.8. Fecal intestinal microbiota analysis
The subjects’ DNA was extracted at CISC using a QIAamp Fast DNA
Stool Mini Kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions with a prior bead beating step in 2 mL micro
centrifuge tubes containing 0.1 mm diameter glass beads, w200 mg
faces, and 1 mL InhibitEX buffer. Bead beating was carried out in a
Mini-Bead Beater apparatus (BioSpec Products, Bartlesville, OK, USA)
with two cycles of shaking for 1 min and incubation on ice between
cycles. The fecal DNA was measured via UV methods (NanoDrop,
Thermo Fisher Scientific, Wilmington, DE, USA), and an aliquot of
every sample was prepared at 20 ng/ml with nuclease-free water for
polymerase chain reactions (PCRs). The V3eV4 hypervariable regions
of the 16S ribosomal ribonucleic acid (rRNA) gene were amplified
using 20 ng of DNA (1 uL diluted aliquot) and 25 PCR cycles con-
sisting of the following steps: 95 C for 20 s, 55 C for 20 s, and
72 C for 20 s. Phusion High-Fidelity Taq Polymerase (Thermo Fisher
Scientific, Wilmington, DE, USA) and S-D-Bact-0341-b-S-17
(CCTACGGGNGGCWGCAG) and S-D-Bact-0785-a-A-21 (GAC-
TACHVGGGTATCTAATCC) primers that target a wide range of bacterial
16S rRNA genes (Klindworth et al., 2013) were used during PCR. The
primers were 6-mer barcoded. Dual barcoded PCR products con-
sisting of w480bp were purified from triplicate reactions with an
Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare,
Little Chalfont, UK) and quantified through Qubit 3.0 and a Qubit
dsDNA HS Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA).
The samples were multiplexed by combining equimolar quantities of
amplicon DNA (100 ng per sample) and sequenced in an Illumina
MiSeq platform with a 2  300 PE configuration (Centro Nacional de
Análisis Genómico, CNAG, Barcelona, Spain). Sample de-multiplexing
was carried out using sequence information from the respective DNA
barcodes using the Je software suite (v.2.0) allowing no errors in the
indexes. Primers were removed from the sequences using Cutadapt
(v.2.8). The resulting reads were then processed using USEARCH
(v.11.0.667) [80]. Forward and reverse reads were merged allowing
for a maximum of 30 mismatches in the overlapping region. Merged
reads were discarded if they were shorter than 350 bp or longer than
500bp. Remaining contigs were filtered using an expected error-
based quality filter as described by Edgar et al. [81]. Filtered con-
tigs were dereplicated and unique sequences were denoised using
the UNOISE3 algorithm to infer Amplicon sequence variants (ASVs).
All the merged reads were subsequently mapped against the
resulting ASVs to produce a count table. Taxonomy was assigned to
the ASVs using the USEARCH sintax algorithm [82] using the SILVA
(v.123) database. The sample counts were rarefied to 17,391 counts
per sample. For downstream machine-learning models, ASVs wereMOLECULAR METABOLISM 42 (2020) 101076  2020 The Author(s). Published by Elsevier GmbH. This is
www.molecularmetabolism.comfurther filtered by abundance, keeping only ASVs that had on average
at least 3 counts per sample (372 ASVs). The raw amplicon
sequencing microbiome data from this study will be deposited in the
European Nucleotide Archive repository.
2.2.9. Plasma metabolomics
Plasma samples (350 mL) were mixed with D2O at a 1:1 volume ratio.
All the homogenized samples were centrifuged (10 min, 4 C, and
13,000 rpm) and transferred to 5 mm NMR tubes for analysis by NMR
spectroscopy. The NMR experiments were conducted at the Chemical
Analysis Facility (CAF, University of Reading, Reading, UK) using a
Bruker AV700 NMR instrument working at 700.19 MHz equipped with
a 5 mm inverse TCI CryoProbe for increased sensitivity (Bruker Bio-
Spin, Rheinstetten, Germany). A standard 1-dimensional NOESY-PR-
1D experiment was conducted on all the samples followed by a
Carr-Purcell-Meiboom-Gill (CPMG) experiment. Both methods applied
a sequence to pre-saturate the water peak. The CPMG experiment was
used to reduce the signal contribution from albumin and lipoproteins
present in the plasma and improve the detection of signals from
smaller molecules. All the samples were analyzed at 300 K. A 65k data
point spectrum (spectral width 14705 Hz) was obtained by recording
128 scans following 8 dummy scans. The spectral phase and baseline
corrections were assessed using MestreNova software (version 10.0
Mestrelab Research, Santiago, Spain). The NMR spectra were refer-
enced to glucose at 5.23 ppm.
2.2.10. Duodenal biopsy analysis
Duodenal biopsies were obtained at baseline and after 4 weeks for
gut microbiota analyses as well as TPH1 expression [83]. Low
bacterial load present in the duodenal biopsies complicated the
retrieval of enough bacterial DNA for standardized PCR procedures
and 16S amplicon sequencing. Therefore, the duodenal microbiota
could not be analyzed. mRNA was isolated using an RNA isolation
protocol optimized for (very small) biopsies. In short, biopsies were
mixed with 300 ml TriPure (Roche, Basel, Switzerland) and ho-
mogenized on ice using a sterile RNAse-free pestle. After brief
centrifugation, 60 ml of chloroform was added. The samples were
then added to a Heavy Phase Lock gel tube (Quanta Bio, Beverly,
MA, USA) and centrifuged (15 min, 12.000g, and 4 C). The
aqueous phase was transferred and mixed with 1 volume of 70%
ethanol. The mixture was added to an RNeasy MinElute spin column
(QIAgen, Tegelen, the Netherlands). RNA was washed according to
the manufacturer’s protocol and eluted in 14 ml RNAse-free water.
The RNA concentration was measured using NanoDrop 1000
(Thermo Fisher Scientific, Landsmeer, the Netherlands). From the
RNA, cDNA was produced according to the manufacturer’s protocol
using a SensiFAST cDNA Synthesis Kit (Bioline, London, UK). The
expression of hTPH1 and h36B4 genes was measured using qPCR
(CFX 384, BioRad, Hercules, CA, USA). Per reaction, 1 ml of 10 mM
Primer Mix (hTPH1 forward: 50-CCCGCTTTTGGCTGAACCTA-30 and
hTPH1 reverse: 50-AGTAGCACGTTGCCAGTTTTT-30 or h36B4 for-
ward: 50-ACGGGTACAAACGAGTCCTG-30, and h36B4 reverse: 50-
GCCTTGACCTTTTCAGCAAG-30), 1 ml RNAse-free water, 5 ml of
SensiFAST SYBR No-ROX (Bioline, London, UK), and 3 ml cDNA
(5 ng/ml) was used. The hTPH1 gene expression was normalized
using 36B4 as a housekeeping gene. For histology, enterochro-
maffin cells were stained for serotonin. In short, 10x images were
taken with a Leica DM microscope. An ROI was set in the images by
a trained pathologist. ImageJ software was used to quantify the
amount of positive serotonin cells per 100 mM2 as previously
described [84].an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 5
Table 1 e Basic and metabolic parameters.
Butyrate (n ¼ 12) Donor FMT (n ¼ 12)
Before After P Before After P *P
BMI, kg/m2 34.3  3.4 34.2  3.7 0.76 33.0  3.5 33.1  3.4 0.35 0.36
Fasting glucose, mmol/l 6.1 [5.7e6.3] 5.7 [5.4e6.5] 0.23 5.6 [5.2e5.8] 5.5 [5.0e5.9] 0.281 0.54
Fasting insulin, pmol/l 70 [59e114] 61 [48e96] 0.25 77 [53e105] 66 [62e83] 0.169 0.81
HbA1c, mmol/l 40 [35e45] 37 [34e44] 0.04 37 [34e39] 35 [33e38] 0.04 0.41
Cholesterol
- Total, mmol/l 5.5  1 5.1  0.8 0.04 5.9  1.2 5.6  1 0.09 0.85
- LDL, mmol/ 3.5 [2.6e4.3] 3.2 [2.8e4] 0.14 3.9 [3.1e4.5] 3.7 [2.8e4.2] 0.27 0.72
- HDL, mmol/l 1.4 [1.2e1.6] 1.4 [1.2e1.5] 0.55 1.6 [1.3e1.8] 1.4 [1.2e1.6] 0.05 0.26
- Triglycerides, mmol/l 1.4 [1.1e1.7] 1.2 [0.9e1.4] 0.03 1.2 [0.8e1.5] 1.3 [0.9e1.4] 0.84 0.11
Glucose Rd, umol/kg.min 38.5 [30.8e47.4] 38.1 [27.5e42.9] 0.21 38.1 [33.4e53.2] 39.9 [27.9e45.9] 0.21 0.32
EGP suppression, % 74.8 [64.8e82.4] 79 [70.2e86.7] 0.87 82.7 [75.7e97.3] 91.2 [73.8e99.7] 0.34 0.81
REE, kcal/day 1761  259 1738  210 0.56 1694  220 1673  205 0.63 0.91
Glycerol Ra suppression, % 66.6 [63.4e69.6] 68.6 [47.8e74.4] 0.58 64.7 [56.8e67.6] 53.5 [44.8e67] 0.31 0.60
FFA suppression, % 89.6  4.9 86.9  5.9 0.09 89.3  7.7 90.1  5.2 0.68 0.15
IHTG, % 4.7 [2.8e11.1] 4.3 [3.5e12.0] 0.91 5.8 [3.9e12.9] 6.1 [3.3e11.8] 0.59 0.77
CRP, mg/ml 2.5 [2.9e5.0] 1.7 [0.9e4.6] 0.38 2.1 [0.9e3.1] 3.2 [1.0e5.2] 0.13 0.10
Creatinine, mmol/l 76  12 76  11 0.82 75  14 74  13 0.67 0.66
SBP, mmHg 134 [100e141] 128 [124e141] 0.35 126 [115e140] 119 [111e138] 0.69 0.45
DBP, mmHg 72 [60e75] 70 [65e77] 0.43 73 [66e75] 68 [63e78] 0.209 0.25
MAP, mmHg 95 [76e98] 91 [87e102] 0.34 91 [85e103] 85 [82e102] 0.34 0.22
HR, beats/min 61 [56e67] 58 [55e63] 0.12 62 [60e70] 63 [59e66] 0.93 0.16
CO, l/min 5.5 [5.2e6.1] 6 [4.9e6.3] 0.53 5.5 [5.1e6.1] 5.5 [5.4e6] 0.21 0.48
SDNN, millisecond 44 [34e55] 64 [50e73] 0.01 49 [41e57] 54 [40e70] 0.53 0.13
Compliance, number of capsules not taken 0 0 0 0
Data are expressed as mean  SD or median [IQR]. *p ¼ change over time between groups. A p value < 0.05 was considered statistically significant. BMI ¼ body mass index,
HbA1c ¼ glycated hemoglobin, HDL ¼ high-density lipoprotein, HOMA-IR ¼ homeostatic model assessment of insulin resistance, LDL ¼ low-density lipoprotein, CRP ¼ c-reactive
protein, SBP ¼ systolic blood pressure, DBP ¼ diastolic blood pressure, EGP ¼ endogenous glucose production, Rd ¼ rate of disappearance (insulin sensitivity), Ra ¼ rate of
appearance, FFA ¼ free fatty acid, REE ¼ resting energy expenditure, IHTG ¼ intrahepatic triglyceride, MAP ¼ mean arterial pressure, HR ¼ heart rate, CO ¼ cardiac output,
SDNN ¼ standard deviation of the normal-to-normal intervals (inter-beat intervals derived from continuous blood pressure recordings after filtering).
Table 2 e DAT and SERT binding.
Butyrate FMT
Before After P Before After P *P
Striatal DAT binding (SNR-BR) 5.21  1.26 4.71  0.87 0.08 4.60  1.22 5.18  1.27 0.11 0.02
Thalamic SERT binding (SNR-BR) 0.46  0.15 0.42  0.15 0.54 0.45  0.18 0.51  0.16 0.21 0.17
Hypothalamic SERT binding (SNR-BR) 0.51  0.26 0.32  0.23 0.12 0.41  0.31 0.53  0.5 0.37 0.08
Data are expressed as mean SD. *p¼ change over time between groups. A p value< 0.05 was considered statistically significant. DAT¼ dopamine transporter, SERT¼ serotonin
transporter, SNR-BR ¼ specific to non-specific binding ratio.
Table 3 e Systemic and duodenal serotonin metabolism.
24 h urine Butyrate, n ¼ 12 FMT, n ¼ 12 *P
Before After P Before After P
5-HIAA per 24h, mmol/l 30 [18e42] 29 [17e34] 0.27 42 [31e74] 33 [25e46] 0.35 0.93
duodenal EC cells, cells/100 uM2 1.2 [1.0e1.7] 1.1 [1.0e1.6] 1.00 1.1 [0.9e1.6] 1.2 [0.9e1.4] 1.00 0.90
Small intestinal biopsy n ¼ 7 n ¼ 7
TPH1 expression, relative to 36B4 0.0027 [0.0013e0.0035] 0.0037 [0.0013e0.0135] 0.49 0.0044 [0.0017e0.0272] 0.0016 [0.0010e0.0053] 0.17 0.22
Data are expressed as median [range]. *p ¼ change over time between groups. 5-HIAA ¼ 5-hydroxyindoleacetic acid (24 h urine), EC ¼ enterochromaffin, TPH1 ¼ tryptophan
hydroxylase 1 (qPCR duodenal cells).
Original Article2.2.11. Power calculation and statistical analysis
The primary endpoints were changes in hypothalamic SERT and
striatal DAT binding, small intestinal TPH1 expression, serotonin
staining, and urinary 5-HIAA levels in relation to peripheral and hepatic
insulin sensitivity, VAS appetite, and hunger scores upon treatment.
Secondary endpoints were changes in fecal short-chain fatty acids and
plasma bile acids, changes in dietary intake, REE, and physical activity6 MOLECULAR METABOLISM 42 (2020) 101076  2020 The Author(s). Published by Elsevier Genergy expenditure in relation to changes in gut microbiota compo-
sition and plasma metabolites. Changes in the intestinal passage time
(Sitzmark capsules), sympathetic tone, and IHTG were determined
before and after the intervention. The sample size was based on
previous studies in which we found a 30% change in the binding ratio
of 123I-FP-CIT to striatal DAT and SERT in the diencephalon upon
intervention (0.65e0.46 with SD 0.15) [85]. Based on this finding, ambH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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sample size calculation was performed with a two-sided significance
level of 0.05 and power of 80% showing that 10 subjects per arm were
needed. Taking into account a 10e20% dropout rate, we included 12
subjects in each arm for a total of 24 subjects.
Depending on the distribution, the data are presented as
mean  standard deviation or median (interquartile range) and tested
when paired (within group change) with either the paired Student’s t
test or Wilcoxon’s signed-rank test and when unpaired (between 2
groups) with the unpaired Student’s t test or ManneWhitney U test. A p
value< 0.05 was considered statistically significant. Spearman’s rank
correlation coefficient was used for correlation analysis.
2.2.12. Machine-learning model
To identify which intestinal bacterial species were the most
discriminative between both groups, we applied the extreme gradient
boosting classification algorithm combined with stability selection
[86]. We applied the extreme gradient boosting (XGBoost) machine-
learning classification algorithm [87] combined with stability selec-





33 [6e60] 28 [10e49] 0.62
VAS hunger,
cm
33  24 27  21 0.42
Data are expressed as mean  SD and median [range]. *p ¼ change over time between




- Acetic acid, umol/g 448 [298e648] 454 [172e755] 0
- Butyric acid, umol/g 94 [59e129] 92 [41e145] 0
- Propionic acid, umol/g 191 [124e281] 196 (104e283] 0
Plasma BAs
- Total, mM 1.03 [0.77e1.85] 1.04 [0.72e1.44] 0
- Primary, mM 0.515 [0.463e0.841] 0.53 [0.312e0.655] 0
- Secondary, mM 0.504 [0.383e0.799] 0.488 [0.38
7e0.708]
0
- Conjugated, mM 0.645 [0.459e0.957] 0.647 [0.400e0.817] 0
- Unconjugated, mM 0.411 [0.249e0.766] 0.359 [0.284e0.568] 0
Data expressed as median [range]. *p ¼ change over time between groups. SCFA ¼ sho
Table 6 e Energy expenditure.
Butyrate
Before After
Excreted Sitzmarks, number 35 [21e45] 44 [36e53]
AEE, kcal/day 908 [540e1281] 818 [588e1016]
Caloric intake, kCal/day 1682 [1493e2015] 1664 [1492e1803]
Fat intake, g 64 [60e83] 62 [54e65]
Protein intake, g 85 [75e95] 79 [64e96]
Fiber intake, g 17 [14e22] 14 [12e19]
Carbohydrate intake, g 165 [143e209] 155 [137e210]
Data are expressed as median [range]. *p ¼ change over time between groups. AEE ¼ a
MOLECULAR METABOLISM 42 (2020) 101076  2020 The Author(s). Published by Elsevier GmbH. This is
www.molecularmetabolism.compredicting the treatment groups. This technique was used on the
microbial composition data (ASVs) and plasma metabolite levels (NMR
peak values). To predict the treatment groups, we used the relative
change (delta) of each variable between baseline and end time point
in separate models for the metabolomics and microbiota dataset.
Each analysis produced a ranked list of the most important variables.
Variable importance was calculated using the permutation feature
importance of the model. The permutation feature importance is
defined as the decrease in a model score when a single feature value
is randomly shuffled [88]. This procedure severs the relationship
between the feature and target, so the decline in the model score is
indicative of how much the model depends on the feature. While the
variables identified by the classification model frequently lead to
statistically significant results, they can also be unstable. In our
approach, we addressed this problem via the stability selection pro-
cedure coupled with the model selection [86]. Variable stability was
reflected in the frequency that a particular variable was identified in
multiple simulations in a re-randomized dataset. Stability selection
was performed by randomly subsampling 80% and the model wasFMT *P
Before After P
43 [14e68] 49 [24e78] 0.21 0.22
26  27 31  27 0.44 0.25
groups. VAS ¼ visual analogue score.
FMT *P
P Before After P
.72 320 [163e575] 320 [163e576] 0.06 0.16
.86 96 [55e133] 66 [35e96] 0.07 0.55
.53 167 [97e225] 132 [96e167] 0.53 0.53
.24 1.83 [0.92e2.46] 1.53 [1.07e3.53] 0.69 0.60
.18 0.847 [0.371e1.511] 0.85 [0.447e2.317] 0.53 0.16
.27 0.629 [0.459e1.522] 0.622 [0.365e1.015] 0.18 0.81
.31 1.032 [0.462e1.746] 0.768 [0.625e0.817] 0.53 1.00
.24 0.524 [0.356e0.88] 0.476 [0.26e0.689] 0.530 0.73
rt-chain fatty acid, BA ¼ bile acid.
FMT *P
P Before After P
0.18 40 [30e52] 41 [23e54] 0.53 0.12
0.32 925 [433e1301] 750 [371e1187] 0.15 0.95
0.1 1761 [1381e2034] 1777 [1372e2194] 0.24 0.05
0.26 68 [54e82] 68 [53e98] 0.19 0.10
0.19 93 [74e104] 92 [83e100] 0.58 0.64
0.38 16 [13e19] 17 [14e19] 0.34 0.19
0.51 160 [128e198] 188 [137e206] 0.11 0.17
ctive energy expenditure.
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Figure 2: Changes in fecal microbiota composition after butyrate supplementation or allogenic FMT. (A) Biplot of redundancy analysis (RDA axis 1 vs axis 2) of fecal
microbiota data constrained by butyrate vs allogenic FMT treatment variables (before, baseline, and 4 weeks after treatment). Baseline fecal microbiota composition in the post-
RYBG feces donors is also shown. (B) Biplot of deltas from the top 10 amplicon sequence variant (ASV) markers of fecal microbiota after allogenic FMT and butyrate treatment.
AUC ¼ 0.83  0.29. (C) Spider plot depicting a panel of bacterial species that significantly differentiated between the 2 different treatment groups based on changes in the fecal
microbiota composition. The axis reflects the amount of change in % of the bacterial species after either treatment.
Original Article
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Figure 3: Gut microbiota composition. Gut microbiota composition at phylum (A), family (B), genus (C), and species (D) levels stratified by time and group of subjects.
Figure 4: Changes in plasma metabolites. Biplot of redundancy analysis (RDA axis 1 vs axis 2) of the plasma metabolite data constrained by butyrate and allogenic FMT
treatment variables (before, baseline, and 4 weeks after treatment). Baseline plasma metabolites in the post-RYBG feces donors is also shown. The brackets on the axis labels refer
to the proportion of the constrained variance explained by the respective axis/RDAs. In this case, the constrained variance was 7.8% of the total variance.then tested on the remaining 20% of the data not used in the training.
This was repeated 100 times. Receiver operating characteristics area
under the curve (ROC AUC) scores were computed each time and
averaged for the final test ROC AUC. A permutation (randomization
test) was used to evaluate statistical validity of the results. In the
permutation test, the outcome variable was randomly reshuffled
1,000 times while the corresponding omics profiles were maintained
intact [89]. We used Python v3.7 (www.python.org) with Numpy,
Scipy, and Scikit-learn [90] packages to implement the machine-
learning model and 10-fold cross-validation to estimate optimal
hyperparameters.MOLECULAR METABOLISM 42 (2020) 101076  2020 The Author(s). Published by Elsevier GmbH. This is
www.molecularmetabolism.com3. RESULTS
3.1. Participants’ baseline characteristics
Between 2015 and 2017, we included 24 treatment-naïve subjects
with metabolic syndrome aged between 50 and 70 years who were
randomized to receive either an autologous (placebo) FMT and daily
oral ingestion of butyrate for 4 weeks (butyrate group, n ¼ 12) or
allogenic (post-RYGB donor) FMT and placebo capsules (FMT group,
n ¼ 12). In this regard, FMT donors 2, 4, and 5 were used twice,
donors 3 and 6 were used once, and donor 1 was used three times.
The baseline patient characteristics are presented in Table 1 andan open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 9
Original ArticleSupplementary Table 1. All of the subjects were insulin resistant
(homeostasis model assessment for insulin resistance; HOMA-
IR 2.5). Six post-RYGB surgery donors were included, 3 males and 3
females, who were matched by sex to the subjects in the allogenic
FMT group (Supplementary Table 1). Both treatments, daily oral
ingestion of butyrate and a single FMT, were well tolerated and no side
effects or serious adverse events occurred (Supplementary Table 2).
Compliance was verified in all of the subjects and no differences were
found between the 2 groups. There were no significant changes in
body weight, most hemodynamic measurements, and dietary intake
(Tables 1 and 6). However, HbA1c, total cholesterol, and triglycerides
significantly decreased after butyrate treatment, whereas HbA1c was
significantly decreased upon allogenic post-RYGB FMT (Table 1). NoFigure 5: Correlations between changes in gut microbiota and striatal DAT binding
right panel: p values). Changes in Prevotella copri correlated inversely with changes in D
Spearman’s correlation values; right panel: p values). Changes in Bacteroides uniformis p
10 MOLECULAR METABOLISM 42 (2020) 101076  2020 The Author(s). Published by Elsevier Geffect on body weight or glucose metabolism was observed after donor
FMT. Finally and in line with our previous studies [53,57], fecal SCFAs
and bile acids after either oral butyrate or post-RYGB FMT did not
significantly change (Table 5).
3.2. Effect of donor FMT vs butyrate on brain SERT and DAT
After 4 weeks of treatment, a decrease after butyrate treatment and an
increase after post-RYGB FMT in striatal DAT binding was observed
(p ¼ 0.02) (Table 2 and Figure 1A). Heart rate variability (expressed as
SDNN) significantly increased 4 weeks after oral butyrate but not after
post-RYGB donor FMT treatment (Table 1). VAS appetite and hunger
scales did not change before and after 4 weeks of treatment (Table 4).
A positive trend was observed in brain (hypo)thalamic SERT binding. (A) Allogenic post-RYGB FMT donor group (left panel: Spearman’s correlation values,
AT binding (rho ¼ 0.50, p value ¼ 0.1). (B) Butyrate intervention group (left panel:
ositively correlated with changes in DAT binding (rho ¼ 0.70, p value ¼ 0.02).
mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ratios in the FMT group (Table 2 and Figure 1B,C). We found no
changes in 5-HIAA or duodenal TPH1 mRNA expression and entero-
chromaffin cell serotonin staining (Table 3).
3.3. Effect of donor FMT vs butyrate on insulin sensitivity
In line with our previous studies [53,57], no effect of either post-RYGB
donor FMT or oral butyrate on hepatic insulin sensitivity (EGP sup-
pression) and peripheral insulin sensitivity (Rd) was observed (Table 1
and Supplementary Figure 2). No significant effect was observed on
glucoregulatory hormones (Supplementary Table 3) or insulin action in
adipose tissue, determined as the suppression of the glycerol rate of
appearance and IHTG content (Table 1). In line with our previouslyFigure 6: Correlations between changes in plasma metabolites and change in stri
correlation values, right panel: p values). Changes in betaine and glycine correlated positive
panel: Spearman’s correlation values, right panel: p values). All 4 metabolites correlated
(rho ¼ 0.63, p value ¼ 0.04).
MOLECULAR METABOLISM 42 (2020) 101076  2020 The Author(s). Published by Elsevier GmbH. This is
www.molecularmetabolism.compublished results, no significant differences after either intervention in
active energy expenditure as measured via an accelerometer and in-
testinal transit time were observed (Table 6).
3.4. Fecal microbiota and plasma metabolites after post-RYGB
donor FMT compared to butyrate correlated with DAT
After post-RYGB donor FMT, we observed a shift in fecal microbiota
composition toward the donors’ composition (Figure 2A). The gut
microbiota composition of the donors is shown in Supplementary
Figure 3. We found that fecal microbiota including Parabacteroides
distasonis, Clostridiales sp., Eubacterium coprostanoligenes, Alistipes,
Prevotella copri, Bifidobacterium sp., and Bacteroides uniformis wereatal DAT binding. (A) Allogenic post-RYGB FMT donor group (left panel: Spearman’s
ly with change in DAT without reaching significance. (B) Butyrate intervention group (left
positively with changes in DAT with glycine (rho ¼ 0.61, p value ¼ 0.05) and lysine
an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 11
Original Articlealtered after post-RYGB donor FMT, as shown in a PCA plot as a
qualitative visualization (Figure 2B), while treatment with oral butyrate
resulted in a change in, among others, Bacteroides uniformis
(Figures 2C and 3). Regarding changes in fasting plasma metabolites,
after allogenic FMT, a shift was observed toward the FMT donor
plasma metabolite profile (Figure 4), altering plasma lysine, glycine,
methionine, and betaine (Supplementary Figure 4). Increases in fecal
levels of Bacteroides uniformis were significantly associated with an
increase in DAT (r ¼ 0.7, p < 0.05), whereas increases in P. copri
showed an inverse association (r ¼ 0.5, p ¼ 0.1) (Figure 5).
Moreover, with regard to correlations between changes in plasma
metabolites and striatal DAT binding ratios, in the butyrate treatment
group, changes in plasma glycine and lysine levels significantly
correlated with DAT (Figure 6B), whereas plasma betaine and glycine
correlated with DAT after FMT (Figure 6A). Changes in BacteroidesFigure 7: Correlations between changes in plasma metabolites and gut microbiota
right panel: p values). Bacteroides uniformis correlated negatively with all 4 metabolites wi
Butyrate intervention group (left panel: Spearman’s correlation values, right panel: p values
(p ¼ 0.01, p ¼ 0.04, and p ¼ 0.03) and a positive trend was observed with Prevotella
12 MOLECULAR METABOLISM 42 (2020) 101076  2020 The Author(s). Published by Elsevier Guniformis were significantly inversely correlated with changes in
plasma betaine and lysine after FMT (Figure 7A), whereas upon oral
butyrate, changes in Bacteroides uniformis showed a significant linear
correlation with changes in plasma glycine, betaine, and lysine
(Figure 7B).
4. DISCUSSION
In line with our previous studies [53,57], in the current randomized
controlled trial, no significant effect of either daily oral butyrate or
donor feces derived from post-RYGB patients was observed in the
treatment-naïve human subjects with metabolic syndrome on either
body weight or insulin sensitivity as measured by the gold-standard
HIEC. However, the (albeit modest) significant change in human
brain striatal DAT between both groups after 4 weeks was. (A) Allogenic post-RYGB FMT donor group (left panel: Spearman’s correlation values,
th betaine (rho ¼ 0.61, p value ¼ 0.03) and lysine (rho ¼ 0.8, p value ¼ 0.001). (B)
). Bacteroides uniformis correlated significantly with plasma glycine, betaine, and lysine
copri.
mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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associated with alterations in both gut microbiota composition and
plasma metabolites involved in the methionine/S-adenosylmethio-
nine (SAMe) cycle. Interestingly, this pathway is known to be
essential for neurotransmitter synthesis such as dopamine and
serotonin. Collectively, these data suggest that gut microbiota play a
role in the human brain dopaminergic system and therefore might
affect food intake. Whether this is mediated via vagus nerve
signaling [91] and plasma metabolites involved in the SAMe
pathway remains to be determined. Thus, although the interventions
did not result in clinically significant changes, they are hypothesis
generating. DAT is a presynaptic membrane protein expressed in
dopaminergic terminals that regulates synaptic and extracellular
dopamine by facilitating its re-uptake into presynaptic terminals.
This enables the important process of fine-tuning dopamine
signaling, which is essential in reward processing and behavioral
learning [92]. Changes in DAT expression are associated with
neurological and psychiatric disorders such as ADHD, autism, and
Parkinson’s disease (PD) [93]. In line with our findings, previous
studies in PD patients (who were characterized by an altered striatal
DAT expression due to nigrostriatal dopaminergic degeneration)
have shown altered fecal P. copri levels compared to controls [94],
underscoring the role of the gut-brain axis and more specific the
enteric nervous system in human disease [95,96]. In this respect,
our observation of an altered heart rate variability after treatment
with butyrate also suggests the involvement of vagal nerve signaling
in the modulation of the gut-brain axis via changes in microbiota.
This is in line with accumulating data in animals pointing toward the
influence of the gut microbiota on motivational behavior through the
vagal nerve [91,97]. Vagal afferents can be activated by gut
endocrine cell secretion of serotonin gut peptides and also directly
by gut microbiota-derived metabolites such as SCFA butyrate [98].
The vagus nerve projects to the nucleus solitarius of the brainstem.
This nucleus then projects to many brain regions, including the
paraventricular nucleus (PVN) of the hypothalamus and the ventral
tegmental area in the midbrain [99]. These projections could play a
role in the observed changes in striatal DAT and might be important
pathways in the microbiota gut-brain food intake as well as glucose
metabolism axis, but more detailed studies are necessary to explore
these pathways in humans.
Although we observed a positive trend in (hypo)thalamic SERT
binding in the FMT group, we found no significant changes in 24 h
5-HIAA secretion, indicative of whole body serotonin concentrations.
Serotonin staining in EC cells and the TPH1 mRNA expression in the
duodenal tissue biopsies before and after the intervention were
unchanged in both groups. However, other plasma metabolites
including lysine, glycine, methionine, and betaine significantly
changed after treatment, all correlating with changes in DAT
binding, more markedly upon treatment with butyrate. In this re-
gard, Colosimo et al. [100] recently showed that microbiota-derived
amine-based neurotransmitter receptor agonists including lysine
affect histamine receptor H4 (HRH4) signaling in the brain. Although
lysine, an essential amino acid, has previously been associated with
reduced anxiety and stress response in both animals and humans
[101] mediated through changes in serotonin in the central amyg-
dala [102] and gut [103] in rats, to the best of our knowledge, our
study is the first to report a link with dopamine via DAT. Methionine,
betaine, also known as trimethylglycine, and glycine are all involved
in one-carbon (C1) metabolism and the SAMe cycle [104], which are
interrelated with dopamine and serotonin metabolism. In humans,MOLECULAR METABOLISM 42 (2020) 101076  2020 The Author(s). Published by Elsevier GmbH. This is
www.molecularmetabolism.combetaine and methionine are dietary methyl donors from which SAMe
can be synthesized, which is the body’s main methyl donor, found
in all tissues but particularly liver cells and essential to numerous
cellular methyl transfer reactions such as DNA methylation (crucial
in epigenetics) and the formation of neurotransmitters, including
serotonin and dopamine [105]. Unsurprisingly, low SAMe has been
linked to mood disorders characterized by dopamine and serotonin
depletion such as major depression [106,107]. Indeed, depressed
rats had lower SAMe compared to controls, which increased after
treatment with probiotics (lactic acid bacteria Lactobacillus helve-
ticus R0052 and Bifidobacterium longum R0175), while elevated
plasma dopamine in the depressed rats was lowered [108].
Our randomized controlled trial also has certain limitations,
including the small sample size study executed in Caucasian sub-
jects only and thus needs confirmation in a larger RCT including
subjects with different ethnicities [109]. As dietary intake was
stable, the observed effects on the brain were most likely driven by
altered intestinal microbiota. However, using a single donor FMT
might not be enough to induce a durable effect, although in one of
our previous studies, multiple FMTs did not have any significant
metabolic effects in metabolic syndrome subjects [52]. Second, due
to ethical (radiation exposure) constraints, we were only able to
determine SERT and DAT on 2 occasions, whereas a 12-week time
point would have been a valuable addition to study the long-term
effects. We did not assess the effect of our interventions on food
reward-related outcomes such as food behavior-related question-
naires or MRI imaging with computer calculations. Nevertheless, our
intervention study provides further evidence for the existence of a
microbiota gut-brain axis in humans possibly involving the striatal
dopaminergic system.
5. CONCLUSION
This study demonstrated that modulating gut microbiota composition
or increasing one of its major metabolites intraluminally affects striatal
DAT binding in humans. These changes were associated with alter-
ations in Bacteroides uniformis and Prevotella spp. abundance as well
as with metabolites involved in the methionine/S-adenosylmethionine
(SAMe) cycle, an important pathway in neurotransmitter synthesis.
Although our results are still mainly hypothesis generating due to the
small sample size, we speculate that the gut milieu affects vagal af-
ferents projecting to the brain stem, resulting in modulation of neuronal
dopaminergic circuits involved in hedonic regulation of feeding
behavior.
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